Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyCHRS -1.72%42 PB Ratio is 2.79 as of Jul. 15, 2026, which is 70% below its 10-year median of 9.24. GuruFocus rates CHRS with a GF Score™ of 42/100 and a GF Value™ of $0.78 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,228 Biotechnology companies, Coherus Oncology ranks better than 50.57% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Coherus Oncology's share price is $1.425. Coherus Oncology's Book Value per Share for the quarter that ended in Mar. 2026 was $0.51. Hence, Coherus Oncology's PB Ratio of today is 2.79.
The historical rank and industry rank for Coherus Oncology's PB Ratio or its related term are showing as below:
CHRS'
s PB Ratio Range Over the Past 10 Years
Min: 0.79 Med: 9.24 Max: 79.32
Current: 2.79
During the past 13 years, Coherus Oncology's highest PB Ratio was 79.32. The lowest was 0.79. And the median was 9.24.
CHRS's PB Ratio is ranked better than 50.57% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs CHRS: 2.79
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Coherus Oncology was 93.80% per year. The lowest was -52.60% per year. And the median was 49.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Coherus Oncology PB Ratio Related Terms
Coherus Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coherus Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Coherus Oncology (CHRS) has a PB Ratio of 2.79 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Coherus Oncology and its competitors. This is 70% below median its historical median of 9.24. Over the past decade, Coherus Oncology's PB Ratio has ranged from 0.79 to 79.32. According to the industry distribution chart, Coherus Oncology ranks #607 out of 1228 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Coherus Oncology's PB Ratio too high?
Coherus Oncology's current PB Ratio of 2.79 is 70% below median its 10-year median of 9.24. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 79.32. The Biotechnology industry median PB Ratio is 2.90. Coherus Oncology's value of 2.79 is 3.6% below this industry median. Based on the distribution chart, Coherus Oncology ranks #607 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's PB Ratio compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #607 out of 1228 companies for PB Ratio. This puts Coherus Oncology in the upper half of its industry. The industry median PB Ratio is 2.90. Coherus Oncology's value of 2.79 is 3.6% below this benchmark. Historically, Coherus Oncology's own PB Ratio has ranged from 0.79 to 79.32 over the past decade. While the company's 10-year median is 9.24 vs. the industry median of 2.90, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current PB Ratio of 2.79 is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current PB Ratio is 2.79, which is 70% below median its own 10-year median of 9.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.78, compared to a current price of $1.43 — trading 82.7% above its estimated fair value. The current PB Ratio is 2.79, which is 70% below median its 10-year median of 9.24 and 3.6% below the Biotechnology industry median of 2.90. Coherus Oncology's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current PB Ratio is 2.79 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.43 is trading 82.7% above its estimated GF Value™ of $0.78.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for CHRS:
PB Ratio: 2.79 (70% below median its 10-year median of 9.24)
GF Value™: $0.78 vs. price of $1.43 (82.7% above fair value)
Industry Position: 3.6% below the Biotechnology median (#607 of 1228)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for CHRS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
